LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025 /EINPresswire / -- What has been the historic growth trend in the abrysvo or arexvy global market and what is expected in the coming years?

GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

Vaccines sales declined 3% in 2024, reflecting pressures on Arexvy and Shingrix in the U.S. However, Arexvy remains the market leader, and international uptake is gaining momentum. Emily Field ...

Concerns about GBS arose during the review of safety data from clinical trials prior to the approval of Abrysvo (manufactured by Pfizer) and Arexvy (manufactured by GlaxoSmithKline), according to ...

After a blockbuster burst onto the market last year, sales of the RSV vaccine Arexvy nosedived this season. In a similar pattern already seen in the third quarter, Arexvy sales in the fourth ...

Vaccine sales fell 14% (-11% at constant currency) to 2.21 billion pounds, primarily impacted by lower demand for Arexvy related to a more limited ACIP recommendation in the U.S. and channel ...

GSK has counted the cost of narrower US recommendations on the use of RSV vaccines, which caused a 51% decline in sales of its Arexvy shot in 2024, but still managed to post reasonable sales ...

driven by a 19% decline in sales of its flu shots and a 52% plunge for its respiratory treatment Arexvy. Shares are up 6.7% at 14.73 pounds.([email protected]) ...

Vaccine sales fell 14% to £2.21B, with Arexvy sales down 70%, while Specialty Medicines grew 14% to £3.29B, and HIV drug revenue rose. Brand New Membership Level: Benzinga Trade Alerts Vaccine ...

WHAT TO WATCH --VACCINES: Investors will eye sales figures for two of GSK's key vaccines, shingles vaccine Shingrix and respiratory syncytial virus vaccine Arexvy, both of which performed poorly ...

In the US Food and Drug Administration (FDA) study, officials combed through vaccine reaction data on two RSV jabs, called Abrysvo and Arexvy, documented between May 2023 and July last year.

Vaccine sales reflects the challenges we've seen from external pressures in the U.S. and China for Arexvy and Shingrix. Going forward, we expect these to continue in 2025, but equally remain ...